A Case for Optimism | The Dermatologist

Dr. Feldman

As we enter the post-holiday winter doldrums, with shorter, darker days, it can be easy to focus on the negative. But there is still so much to be positive about, as a surgeon I know pointed out. He said, “We live in the best 1% of times in all of human history.  In America, we live in the top 1% of all the people living in those times.  And if you are a doctor in America, you are blessed to be living among the top 1% of Americans.  If you are a doctor in America and are pessimistic about your life, there’s something very wrong.”

As a dermatologist, I find it especially difficult to remain pessimistic in the face of all the amazing advancements in this field. In this issue, Adam Friedman, MD, FAAD, discusses the great potential of cannabinoids for treating a variety of skin ailments. With the increasing acceptance of cannabis for both medical and recreational purposes, research into its uses has been growing, resulting in a host of promising new treatments for psoriasis, atopic dermatitis, acne, scleroderma, and even melanoma. You can read about it beginning on page 33.

Of course, a big part of learning something new is “recognizing that what you used to know just ain’t so,” to paraphrase family physician, Dr John Dykers. We spoke with 2 experts about the new melanoma guidelines, which were updated late last year for the first time since 2011, and what practical considerations those changes may have for dermatologists, starting on page 45. 

As positive as many changes can be, the process of change can often still be quite difficult, and we should remember that when dealing with patients. Counseling someone with hidradenitis suppurativa to lose weight may be undeniably beneficial for their skin condition, but harder for them to put into effect. We outlined several strategies to help, beginning on page 42. 

Despite all the reasons for positivity that surround us, people have a powerful tendency to focus only on the negative. Hopefully, this will be the year that you and your patients change that outlook. 

Steven R. Feldman, MD, PhD

Chief Medical Editor

Dr Feldman is with the Center for Dermatology Research and the Departments of Dermatology, Pathology, and Public Health Sciences at Wake Forest University School of Medicine in Winston-Salem, NC

Source link

Medical News & Information


This may be because of a mistyped URL, a faulty referral from another website, an out of date search engine listing, or the page may have moved. However, we’re happy to write you a referral to visit one of these MDLinx products.

Medical News Articles


All the best medical articles in 32 specialties and 800 subspecialties from over 2,000 peer-reviewed medical journals are summarized, ranked and sorted daily keep you current in less than 5 minutes a day.

Smartest Doc TM


Compete in a daily competition to find out if you’re the Smartest Doc in America! Or, build your personal Review scorecard using thousands of free self-assessment questions to aid exam prep and keep you sharp.

MDLinx Career Center


Search medical job listings and have job opportunities sent directly to your email inbox. Post your CV and have the top medical recruiters bring your dream job to YOU!

Source link

Inflarx (IFRX) Downgraded to Hold at Zacks Investment Research

Inflarx (NASDAQ:IFRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

A number of other equities analysts have also weighed in on the company. Credit Suisse Group initiated coverage on Inflarx in a research note on Monday, December 10th. They set an “outperform” rating and a $47.00 price objective on the stock. ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Robert W. Baird initiated coverage on Inflarx in a research note on Monday. They set an “outperform” rating and a $62.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $46.88.

NASDAQ IFRX opened at $33.32 on Wednesday. The firm has a market cap of $813.73 million, a price-to-earnings ratio of -11.33 and a beta of -0.69. Inflarx has a fifty-two week low of $20.31 and a fifty-two week high of $42.83.

Inflarx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, November 21st. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.10. Equities analysts forecast that Inflarx will post -1.3 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc raised its position in Inflarx by 137.4% in the third quarter. Vanguard Group Inc now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares during the period. Vanguard Group Inc. raised its position in Inflarx by 137.4% in the third quarter. Vanguard Group Inc. now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares during the period. Scopia Capital Management LP purchased a new stake in Inflarx in the third quarter valued at $7,038,000. Jane Street Group LLC purchased a new stake in Inflarx in the third quarter valued at $278,000. Finally, Renaissance Technologies LLC purchased a new stake in Inflarx in the third quarter valued at $665,000. Institutional investors own 57.10% of the company’s stock.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

See Also: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

UDR, Inc. (UDR) Touches $43.52 High on Jan, 30; Xbiotech (XBIT) SI Decreased By 5.26%

UDR, Inc. (NYSE:UDR) Logo

The stock of UDR, Inc. (NYSE:UDR) reached all time high today, Jan, 30 and still has $47.44 target or 9.00% above today’s $43.52 share price. This indicates more upside for the $12.98 billion company. This technical setup was reported by Barchart.com. If the $47.44 PT is reached, the company will be worth $1.17B more. The stock increased 0.60% or $0.26 during the last trading session, reaching $43.52. About 190,724 shares traded. UDR, Inc. (NYSE:UDR) has risen 8.99% since January 30, 2018 and is uptrending. It has outperformed by 8.99% the S&P500. Some Historical UDR News: 25/04/2018 – CORRECT: UDR SEES FY FFO/SHR AS ADJ $1.91 TO $1.95, EST. $1.93; 25/04/2018 – UDR Inc 1Q Net $81.8M; 27/03/2018 – UDR Inc Raises Dividend to 32.25c Vs. 31c; 25/04/2018 – UDR INC UDR.N – QTRLY YEAR-OVER-YEAR SAME-STORE REVENUE GROWTH WAS 3.0 PERCENT; 25/04/2018 – UDR SEES 2Q FFO/SHR AS ADJ 43C TO 45C, EST. 49C; 17/04/2018 – UDR INC UDR.N : BARCLAYS RAISES TARGET PRICE TO $39 FROM $38; 27/03/2018 UDR Announces A 4% Annualized Common Dividend Increase For 2018; 27/03/2018 – UDR BOOSTS QTR DIV TO $0.3225 FROM $0.31; EST. $0.3225; 25/04/2018 – UDR Inc 1Q EPS 30c; 25/04/2018 – UDR SEES FY FFO/SHR AS ADJ $1.76 TO $1.80, EST. $1.93

Xbiotech Inc (NASDAQ:XBIT) had a decrease of 5.26% in short interest. XBIT’s SI was 1.65 million shares in January as released by FINRA. Its down 5.26% from 1.74 million shares previously. With 23,200 avg volume, 71 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 8.38%. The stock increased 3.00% or $0.19 during the last trading session, reaching $6.45. About 47,406 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 30, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $230.96 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – Nasdaq” on January 29, 2019, also Nasdaq.com with their article: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” published on January 28, 2019, Globenewswire.com published: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” on January 23, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Seekingalpha.com and their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019 as well as Globenewswire.com‘s news article titled: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” with publication date: August 10, 2018.

Investors sentiment decreased to 1.04 in Q3 2018. Its down 0.04, from 1.08 in 2018Q2. It is negative, as 22 investors sold UDR, Inc. shares while 113 reduced holdings. 41 funds opened positions while 99 raised stakes. 251.18 million shares or 1.98% more from 246.29 million shares in 2018Q2 were reported. Ameriprise reported 0% of its portfolio in UDR, Inc. (NYSE:UDR). Ontario – Canada-based 1832 Asset Mgmt L P has invested 0% in UDR, Inc. (NYSE:UDR). Livforsakringsbolaget Skandia Omsesidigt reported 2,366 shares or 0.01% of all its holdings. 36,377 were reported by Norinchukin Bank The. Parkside Bank And Trust holds 36 shares or 0% of its portfolio. New Mexico Educational Retirement Board invested in 23,900 shares. Sg Americas Limited Liability Corp invested 0.02% of its portfolio in UDR, Inc. (NYSE:UDR). Fca Tx has invested 0.15% in UDR, Inc. (NYSE:UDR). Employees Retirement Of Texas stated it has 38,513 shares or 0.02% of all its holdings. M&R Capital Mgmt Incorporated invested 0.01% in UDR, Inc. (NYSE:UDR). Hsbc Pcl holds 0.01% or 134,686 shares. Citigroup stated it has 459,387 shares. Earnest Limited Liability Corp holds 0% or 128 shares. Mason Street Advisors Ltd Liability Corp invested in 37,628 shares. Oakbrook Ltd, a Illinois-based fund reported 14,205 shares.

Since August 17, 2018, it had 0 buys, and 9 sales for $6.84 million activity. $412,155 worth of stock was sold by ALCOCK HARRY G on Monday, November 26. Davis Jerry A also sold $404,400 worth of UDR, Inc. (NYSE:UDR) shares. $1.65M worth of UDR, Inc. (NYSE:UDR) shares were sold by TOOMEY THOMAS W. Troupe Warren L had sold 10,000 shares worth $412,870. The insider SAGALYN LYNNE B sold $192,829.

UDR, Inc. is an independent real estate investment trust. The company has market cap of $12.98 billion. The firm invests in the real estate markets of the United States. It has a 62.44 P/E ratio. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities.

Analysts await UDR, Inc. (NYSE:UDR) to report earnings on February, 5. They expect $0.49 earnings per share, up 2.08% or $0.01 from last year’s $0.48 per share. UDR’s profit will be $146.19M for 22.20 P/E if the $0.49 EPS becomes a reality. After $0.49 actual earnings per share reported by UDR, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

UDR, Inc. (NYSE:UDR) Institutional Positions Chart


Source link

XBiotech Inc. (XBIT) Reaches $6.49 52-Week High; Arca Biopharma (ABIO) Shorts Up By 11.12%

XBiotech Inc. (NASDAQ:XBIT) Logo

Arca Biopharma Inc (NASDAQ:ABIO) had an increase of 11.12% in short interest. ABIO’s SI was 321,800 shares in January as released by FINRA. Its up 11.12% from 289,600 shares previously. With 1.07 million avg volume, 0 days are for Arca Biopharma Inc (NASDAQ:ABIO)’s short sellers to cover ABIO’s short positions. It closed at $0.44 lastly. It is down 59.24% since January 30, 2018 and is downtrending. It has underperformed by 59.24% the S&P500.

The stock of XBiotech Inc. (NASDAQ:XBIT) hit a new 52-week high and has $7.01 target or 8.00% above today’s $6.49 share price. The 9 months bullish chart indicates low risk for the $232.42M company. The 1-year high was reported on Jan, 30 by Barchart.com. If the $7.01 price target is reached, the company will be worth $18.59M more. The stock increased 3.65% or $0.23 during the last trading session, reaching $6.49. About 63,140 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 30, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – Nasdaq” on January 29, 2019, also Seekingalpha.com with their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019, Globenewswire.com published: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” on August 10, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” published on October 31, 2018 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” with publication date: December 03, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $232.42 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Source link

XBiotech Inc. (XBIT) Increases Again; Strong Momentum for Buyers

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 3.35% or $0.21 during the last trading session, reaching $6.47. About 90,063 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 30, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
The move comes after 9 months positive chart setup for the $231.75M company. It was reported on Jan, 30 by Barchart.com. We have $6.73 PT which if reached, will make NASDAQ:XBIT worth $9.27 million more.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” on January 28, 2019, also Seekingalpha.com with their article: “XBiotech’s bermekimab shows positive effect dermatitis pilot study; shares up 28% premarket – Seeking Alpha” published on September 13, 2018, Nasdaq.com published: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” on December 26, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” published on December 12, 2018 as well as Seekingalpha.com‘s news article titled: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” with publication date: January 23, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $231.75 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

High BMI or Skin Disease: Which Would You Choose?

HS

Patients with hidradenitis suppurativa (HS) were more likely trade time off their life to live without skin disease, according to the findings of a recent study. The results showed that patients with either psoriasis or HS and obesity were more impacted by their skin disease than their weight.

 

The study included 79 participants with obesity and psoriasis or HS who completed a survey. Differences in impact on quality of life between skin diseases and obesity were assessed using a time-trade-off utility, and analysis adjusted for degree of obesity and disease severity.

 

Participants with HS had a higher body mass index (BMI) compared with those with psoriasis (mean BMI 38.1 kg/m2 vs 34.9 kg/m2, respectively).

__________________________________________________________________

You may also like…

The Burden of Hidradenitis Suppurativa Among Patients With Skin of Color
The Psychosocial Impact of Hidradenitis Suppurativa

__________________________________________________________________

The researchers found that participants with HS or psoriasis were willing to trade a significantly higher proportion of their life to live without skin disease than to live at a normal weight. This persisted after they controlled for weight and disease severity.

In addition, those with HS were willing to trade significantly more years of life to live at a normal weight compared with those with psoriasis.

“In this study population, obesity was more severe in patients with HS than in those with psoriasis,” the researchers concluded. “Even after controlling for relative severity, HS was more problematic for participants in this study than weight when these conditions existed concomitantly.”

One limitation of this study, the researchers noted, was the small sample size and that it was conducted at an academic institution.

Reference

Storer MA, Danesh MJ, Sandhu ME, Pascoe V, Kimball AB. An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. Int J Womens Dermatol. 2018;4(4):198-202. doi:10.1016/j.ijwd.2018.08.009

Source link

Medications,Surgery,Others – Industry News Trend

Hidradenitis Suppurativa Treatment

Hidradenitis Suppurativa Treatment Market Report provides an analytical calculation of the prime challenges faced by this Market currently and in the coming years, which helps Market participants in understanding the problems they may face while operating in this Market over a longer period.

Various Hidradenitis Suppurativa Treatment industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost and revenue.

Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males.Considering the global scenario of the market, North America holds the largest market share due to various factors such as increasing cases of skin diseases and related medical complications.

Ask for Sample of report at- https://www.industryresearch.co/enquiry/request-sample/13716430   

The following Manufactures are included in the Hidradenitis Suppurativa Treatment Market report:

GlaxoSmithKline,Johnson & Johnson,Merck,Pfizer,AbbVie,Allergan,AstraZeneca,

Various policies and news are also included in the Hidradenitis Suppurativa Treatment Market report. Various costs involved in the production of Hidradenitis Suppurativa Treatment are discussed further. This includes labour cost, depreciation cost, raw material cost and other costs.

The production process is analysed with respect to various aspects like, manufacturing plant distribution, capacity, commercial production, R&D status, raw material source and technology source. This provides the basic information about the Hidradenitis Suppurativa Treatment industry.

Hidradenitis Suppurativa Treatment Market Types:

Medications
Surgery
Others

Hidradenitis Suppurativa Treatment Market Applications:

Hospitals
Clinics
Others

Browse more detail information about Hidradenitis Suppurativa Treatment Market Report at: https://www.industryresearch.co/13716430   

Further in the Hidradenitis Suppurativa Treatment Market research report, following points are included along with in-depth study of each point:

Production Analysis- Production of the Hidradenitis Suppurativa Treatment is analysed with respect to different regions, types and applications. Here, price analysis of various Hidradenitis Suppurativa Treatment Market key players is also covered.

Sales and Revenue Analysis- Both, sales and revenue are studied for the different regions of the global Hidradenitis Suppurativa Treatment Market. another major aspect, price, which plays important part in the revenue generation is also assessed in this section for the various regions.

Supply and Consumption- In continuation with sales, this section studies supply and consumption for the Hidradenitis Suppurativa Treatment Market. This part also sheds light on the gap between supple and consumption. Import and export figures are also given in this part.

Other analyses- Apart from the information, trade and distribution analysis for the Hidradenitis Suppurativa Treatment Market, contact information of major manufacturers, suppliers and key consumers is also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

In continuation with this data sale price is for various types, applications and region is also included. The Hidradenitis Suppurativa Treatment Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Regions covered in Hidradenitis Suppurativa Treatment Market report:

  • United States
  • Europe
  • China
  • Japan
  • Southeast Asia
  • India

No.of Pages: 94

Purchase Report at $ 3900 (Single User Licence) at: https://www.industryresearch.co/purchase/13716430

About Industry Research:

Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact Us:

Name: Ajay More

Organization: Industry Research

Phone : +1424 253 0807

Email : [email protected]

Read More Industry News: http://video.myfoxyakima.com/category/334345/theexpresswirecom

Source link

Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting

AUSTIN, Texas, Jan. 28, 2019 (GLOBE NEWSWIRE) — XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2nd, 2019 at the AAD annual meeting being held at the Walter E. Washington Convention Center in Washington, D.C. The presentation, which was accepted as “late-breaking research: clinical trials,” will provide details of the Company’s recent Phase II clinical trial results in 42 HS patients that received 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen.

The study involved two treatment groups of subjects: those who had failed prior anti-TNF therapy (n=24); and those with no prior anti-TNF treatment history (n=18). The study was conducted at eleven different dermatology research centers across the U.S.

The study’s Chair, Dr. Alice Gottlieb, M.D., Ph.D., Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY, commented, “I am looking forward to presenting these very exciting results for a new drug that can help address a significant unmet need for patients suffering from hidradenitis suppurativa.”

A major finding in the study was a significant treatment-related reduction of pain in the HS patients. Pain is widely recognized among experts as a key objective for HS treatment, but this symptom has been largely unaddressed by available approved therapies. No approved monotherapy for HS has shown a significant effect on pain1.

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses2,3. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life4. The global prevalence for HS is estimated at up to 4% of the population3.

About True Human™ Therapeutic AntibodiesXBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements, including declarations regarding management’s beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the “Risk Factors” section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

ContactAshley Oteroaotero@xbiotech.com512-386-2930

1 Only 34 of 122 (28%) of patients treated weekly with adalimumab achieved this endpoint at week 12 in the PIONEER I monotherapy study.2 Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998.3 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. doi: 10.1016/j.jaad.2008.11.911.4 Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57.

Source link

XBiotech Inc. (XBIT) Reaches $6.49 52-Week High; Egerton Capital Uk Llp Has Lifted By $426.14 Million Its Twenty First Centy Fox (FOXA) Stake

Twenty-First Century Fox, Inc. (NASDAQ:FOXA) Logo

Egerton Capital Uk Llp increased Twenty First Centy Fox Inc (FOXA) stake by 34.52% reported in 2018Q3 SEC filing. Egerton Capital Uk Llp acquired 9.26M shares as Twenty First Centy Fox Inc (FOXA)’s stock rose 9.84%. The Egerton Capital Uk Llp holds 36.10 million shares with $1.67 billion value, up from 26.83 million last quarter. Twenty First Centy Fox Inc now has $90.86 billion valuation. The stock decreased 0.31% or $0.16 during the last trading session, reaching $49.08. About 2.78 million shares traded. Twenty-First Century Fox, Inc. (NASDAQ:FOXA) has risen 44.38% since January 28, 2018 and is uptrending. It has outperformed by 44.38% the S&P500. Some Historical FOXA News: 10/04/2018 – Fox Networks U.K. Offices Inspected in EC Probe of Sports Rights; 09/05/2018 – 21st Century Fox Reports Third Quarter Income From Continuing Operations Before Income Tax Expense Of $1.33 Billion And Total Segment Operating Income Before Depreciation And Amortization Of $1; 17/04/2018 – Andrew Wallenstein: Exclusive w/ @gdanielholloway: 21st Century Fox just teamed up with arch rival Disney in a joint bid for TV; 12/04/2018 – RESPONSE TO ANNOUNCEMENT BY THE UK TAKEOVER PANEL; 17/05/2018 – Fox News Promotes Jay Wallace to President and Executive Editor; 03/04/2018 – 21st Century Fox To Create New Private Limited Company; 27/03/2018 – FS Bancorp, Inc. Announces Twenty-First Consecutive Quarterly Dividend and Dividend Increase; 29/05/2018 – NEW: The Walt Disney Company is lining up financing in case Twenty-First Century Fox’s board demands cash as part of Disney’s massive bid for its assets as Comcast prepares a potential all-cash bid to compete with Disney, sources say; 11/04/2018 – The European Commission raided the offices of Twenty-First Century Fox in London; 30/05/2018 – 21ST CENTURY FOX SETS JULY 10, 2018 SPECIAL MEETING FOR VOTE ON

The stock of XBiotech Inc. (NASDAQ:XBIT) hit a new 52-week high and has $7.01 target or 8.00% above today’s $6.49 share price. The 6 months bullish chart indicates low risk for the $232.47M company. The 1-year high was reported on Jan, 28 by Barchart.com. If the $7.01 price target is reached, the company will be worth $18.60M more. The stock increased 6.92% or $0.42 during the last trading session, reaching $6.49. About 220,931 shares traded or 158.01% up from the average. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since January 28, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $232.47 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – GlobeNewswire” on January 23, 2019, also Seekingalpha.com with their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019, Globenewswire.com published: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” on August 10, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” published on October 31, 2018 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” with publication date: December 03, 2018.

Among 4 analysts covering Twenty-First Century Fox (NASDAQ:FOXA), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Twenty-First Century Fox had 5 analyst reports since August 7, 2018 according to SRatingsIntel. The rating was maintained by Macquarie Research on Thursday, September 6 with “Neutral”. Buckingham Research maintained Twenty-First Century Fox, Inc. (NASDAQ:FOXA) rating on Tuesday, August 7. Buckingham Research has “Buy” rating and $52 target. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Thursday, August 9. Morgan Stanley maintained Twenty-First Century Fox, Inc. (NASDAQ:FOXA) rating on Monday, October 15. Morgan Stanley has “Overweight” rating and $53 target. Morgan Stanley maintained the shares of FOXA in report on Thursday, November 8 with “Overweight” rating.

Egerton Capital Uk Llp decreased Alibaba Group Hldg Ltd (NYSE:BABA) stake by 1.17 million shares to 2.34 million valued at $384.83 million in 2018Q3. It also reduced Cintas Corp (NASDAQ:CTAS) stake by 347,306 shares and now owns 647,981 shares. Mastercard Incorporated (NYSE:MA) was reduced too.

Twenty-First Century Fox, Inc. (NASDAQ:FOXA) Institutional Positions Chart

Source link